Article citationsMore>>

Fujita, K., Sugiura, T., Okumura, H., Umeda, S., Nakamichi, N., Watanabe, Y., Suzuki, H., Sunakawa, Y., Shimada, K., Kawara, K., Sasaki, Y. and Kato, Y. (2014) Direct Inhibition and Down-Regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Human. Pharmaceutical Research, 31, 204-215.
https://doi.org/10.1007/s11095-013-1153-x

has been cited by the following article:

• TITLE: Limited Effect of Intravenously Administered Indoxyl Sulfate, a Uremic Toxin, on the Hepatic Transport of Pravastatin in Normal Rats

  AUTHORS: Hideyuki Suga, Yuichi Ichimura, Satomi Otsuka, Kaori Sugaya, Masako Oda, Hiroshi Saitoh

  KEYWORDS: Indoxyl Sulfate, Pravastatin, Drug Interaction, Hepatic Transport, Biliary Excretion

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.9 No.7, July 27, 2018

  ABSTRACT: Indoxyl sulfate (IS) is a typical uremic toxin that extensively accumulates in the plasma of patients with seriously impaired renal function. This study seeks to clarify whether IS exerts a potent modulating effect on the hepatic transport of pravastatin, which is a substrate of both organic anion transporting peptides (OATPs) and multidrug resistance-associated protein (Mrp) 2 in rats. When IS is administered intravenously to the normal rats at a dose of 120 μmol/kg; plasma IS levels are approximately 600 μM after 2 min and 100 μM after 120 min. In rats with acute renal failure (ARF) induced by cisplatin, the area under the curve (AUC) was more than 2.5-fold greater compared with that in the normal rats, indicating that IS accumulates in ARF rats. Intravenously administered pravastatin almost disappeared from the plasma by 60 min post-administration and approximately 55% of dose was excreted in the bile within 60 min. This result suggested that pravastatin was efficiently taken up from the sinusoid into hepatocytes via rat OATPs on the sinusoidal membrane and preferentially transported in the bile mediated by Mrp2 on the canalicular membrane. IS administered intravenously at a dose of 120 μmol/kg caused neither an increase in plasma pravastatin levels nor a decrease in its biliary excretion. In conclusion, the present results demonstrate that single intravenous administration of IS does not interfere with the hepatic transport of pravastatin directly in vivo, which is at variance with the results of previous in vitro studies.